Evidence map›Paper›PMID 42115356›Full record

ArticleScientific reports2026

Design, synthesis, and multitarget evaluation of thiosemicarbazone-sulfonamide hybrids as potent cholinesterase and MAO-A inhibitors with neuroblastoma-associated cytotoxicity.

Khawar Abbas, Mohamed Rahmtalla Elamin, Halil Şenol, Furkan Çakır, Parham Taslimi, Feyzi Sinan Tokali, Nadeem Raza, Mostafa E Salem, Rima D Alharthy, Asif Rasool and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Khawar AbbasInstitute of Chemical Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan.
Mohamed Rahmtalla ElaminDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Halil ŞenolDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, 34093, Istanbul, Turkey.
Furkan ÇakırDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, 34093, Istanbul, Turkey.
Parham TaslimiDepartment of Biotechnology, Faculty of Science, Bartin University, 74110, Bartin, Turkey.
Feyzi Sinan TokaliDepartment of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, 36100, Kars, Turkey.
Nadeem RazaDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Mostafa E SalemDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Rima D AlharthyDepartment of Chemistry, Rabigh Branch, Science & Arts College, King Abdulaziz University, Rabigh, 21911, Saudi Arabia.
Asif RasoolSchool of Chemistry and Chemical Engineering Nanjing university, Nanjing, 210093, China.
Zahid ShafiqInstitute of Chemical Sciences, Bahauddin Zakariya University, Multan, 60800, Pakistan. zahidshafiq@bzu.edu.pk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative disorders and neuroblastoma represent major therapeutic challenges, and multitarget approaches have gained increasing attention. In this study, a series of thiosemicarbazone derivatives (5a-t) was evaluated for their inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase A (MAO-A), together with their cytotoxic effects and molecular interaction profiles. In vitro enzyme assays revealed nanomolar inhibition for several compounds. Notably, compound 5n exhibited potent and balanced multitarget activity with IC

Indexed as

Cholinesterase InhibitorsMonoamine Oxidase InhibitorsNeuroblastomaSulfonamidesThiosemicarbazonesAcetylcholinesteraseAntineoplastic AgentsButyrylcholinesteraseCell Line, TumorDrug DesignHumansKineticsMolecular Docking SimulationMonoamine OxidaseStructure-Activity RelationshipAcetylcholinesteraseAntineoplastic AgentsButyrylcholinesteraseCholinesterase InhibitorsMonoamine OxidaseMonoamine Oxidase InhibitorsSulfonamidesThiosemicarbazonesCholinesteraseMonoamine oxidase ANeuroblastomaNeurodegenerative disordersThiosemicarbazone

Identifiers

PMID42115356
PMCPMC13190835

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.